Publications
Decision by U.S. Court of Appeals for the Federal Circuit in Myriad Remand Mirrors Reasoning in NYIPLA Amicus Brief
On August 16, 2012, the U.S. Court of Appeals for the Federal Circuit (“Federal Circuit”) released its highly anticipated decision in Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 2010-1406 (Fed. Cir. Aug. 16, 2012) (“Myriad IV“), concerning the patent eligibility of isolated DNA under 35 U.S.C. § 101, on remand from the U.S. Supreme Court. See Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794 (2012) (“Myriad III“).
In Myriad IV, the Federal Circuit largely followed the rationale of its prior decision in the case. Cf. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir. 2011) (“Myriad II“). The Myriad IV majority decision reflects a reasoning similar to the positions set forth in the NYIPLA Amicus Brief filed in this case. Compare Brief for Amicus Curiae N.Y. Intellectual Property Law Ass’n in Support of Neither Party, Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 2010-1406 (Fed. Cir. June 15, 2012), available at http://www.nyipla.org/images/nyipla/ Documents/Amicus%20Briefs/Myriad%20_2010_1406.pdf (“NYIPLA Amicus Brief”), with Myriad IV, No. 2010-1406 (Fed. Cir. Aug. 16, 2012). Anthony F. Lo Cicero and Charles R. Macedo of Amster, Rothstein & Ebenstein LLP and Ronald M. Daignault and Matthew B. McFarland of Robins, Kaplan, Miller & Ciresi LLP prepared the NYIPLA Amicus Brief.
